New FDA CDISC requirements for ANDAs [Regulatives / Guidelines]

posted by lechia – C of U, 2016-11-22 23:33 (3006 d 04:41 ago) – Posting: # 16807
Views: 5,778

Thank you for your response, David.

A related question is whether pilot studies that are submitted to the FDA along with the pivotal studies for information/completeness purposes must also follow CDISC standards. The guidance says:

"... all studies with a start date 24 months after the publication date must use the appropriate FDA-supported standards, formats, and terminologies ... for NDA, ANDA, and certain BLA submissions."

Not sure how to interpret this. Would only pivotal studies fit this description or any study since any study done on a particular IP since it would be part of the submission? Presumably this would not matter if a study is ANDA or NDA.

Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
75 visitors (0 registered, 75 guests [including 12 identified bots]).
Forum time: 04:15 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5